MedTrace Logo

Pembrolizumab in Patients With Non-Small Cell Lung Cancer and a Performance Status 2

NCT02733159 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2025-02-10

Study results available
· View outcomes & findings →

Summary

This study is to determine that pembrolizumab is safe and tolerable at the selected dose for the treatment of Non-Small Cell Lung Cancer (NSCLC) in patients with a performance status of 2. All patients will receive pembrolizumab.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

pembrolizumab

anti PD-1

Sponsors & Collaborators

Principal Investigators

  • Gary Middleton, Professor · University of Birmingham

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-04
Primary Completion
2023-02-07
Completion
2024-02-05

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02733159 on ClinicalTrials.gov